NCT05142241 2025-11-18Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 TrialNational Cancer Institute (NCI)Phase 2 Active not recruiting14 enrolled